Table 2 Effects of nicotinamide riboside alone and nicotinamide riboside with resveratrol on the primary outcome of 6-month change in 6-min walk in peripheral artery disease

From: Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial

 

Nicotinamide riboside (NR)

Nicotinamide riboside (NR) + resveratrol (R)

Placebo

  
 

Baseline, mean (standard deviation)

6-mo. follow-up, mean (standard deviation)

Within group change, LSMeans (standard error)

Baseline, mean (standard deviation)

6-mo. follow-up, mean (standard deviation)

Within group change, LSMeans (standard error)

Baseline, mean (standard deviation)

6-mo. follow-up, mean (standard deviation)

Within group change, LSMeans (standard error)

NR vs. placebo, LSMeans (90% CI)

NR + R vs. placebo, LSMeans (90% CI)

6-min. walk distance (meters)

339.2

(103.1)

N = 28

343.2 (100.0)

N = 28

+7.0

(8.7)

336.6

(80.8)

N = 33

328.9 (88.1)

N = 33

−6.9

(7.8)

325.6 (112.5)

N = 29

324.6 (89.6)

N = 28

−10.6

(8.5)

+17.6

(+1.8, +∞)

P = 0.08

+3.7

(−11.2, +∞)

P = 0.38

  1. Mixed models for repeated measures (MMRM) were used to compare 6-month change in 6-min walk distance between the NR + resveratrol and placebo groups and between the NR alone and placebo groups using baseline, 3-month, and 6-month values for 6-min walk distance, adjusting for age, sex, race, and baseline 6-min walk. One participant randomized to placebo had a very low baseline value but did not complete follow-up testing, contributing to the differences between the observed mean changes in 6-min walk distance from baseline to follow-up, compared to the least square mean estimate. The a priori statistical analysis plan defined a one-sided P value of <0.10 to define statistical significance.
Back to article page